BRPI0516659A - proteìna de fusão compreendendo um domìnio de bh3 de uma proteìna de bh3 somente - Google Patents

proteìna de fusão compreendendo um domìnio de bh3 de uma proteìna de bh3 somente

Info

Publication number
BRPI0516659A
BRPI0516659A BRPI0516659-4A BRPI0516659A BRPI0516659A BR PI0516659 A BRPI0516659 A BR PI0516659A BR PI0516659 A BRPI0516659 A BR PI0516659A BR PI0516659 A BRPI0516659 A BR PI0516659A
Authority
BR
Brazil
Prior art keywords
protein
fusion protein
domain
fusion
relates
Prior art date
Application number
BRPI0516659-4A
Other languages
English (en)
Inventor
Christophe Bonny
Didier Coquoz
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34927574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516659(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of BRPI0516659A publication Critical patent/BRPI0516659A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROTEìNA DE FUSãO COMPREENDENDO UM DOMìNIO DE BH3 DE UMA PROTEìNA DE BH3 SOMENTE. Esta invenção diz respeito a uma proteína de fusão compreendendo pelo menos uma primeira porção (I) compreendendo uma seqüência de tráfego e pelo menos uma segunda porção (II) compreendendo uma seqüência de domínio de BH3 de tamanho natural ou parcial de uma proteína de BH3 somente, a dita proteína de fusão compreendendo aminoácidos D-enantioméricos na ordem retroinversa em sua porção (I). Além disso, a invenção diz respeito às composições farmacêuticas contendo a dita-proteína de fusão, bem como ao uso da dita proteína de fusão.
BRPI0516659-4A 2004-11-29 2005-11-18 proteìna de fusão compreendendo um domìnio de bh3 de uma proteìna de bh3 somente BRPI0516659A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04028278A EP1661912A1 (en) 2004-11-29 2004-11-29 Fusion protein comprising a BH3-domain of a BH3-only protein
PCT/EP2005/012389 WO2006056370A1 (en) 2004-11-29 2005-11-18 Fusion protein comprising a bh3-domain of a bh3-only protein

Publications (1)

Publication Number Publication Date
BRPI0516659A true BRPI0516659A (pt) 2008-09-16

Family

ID=34927574

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516659-4A BRPI0516659A (pt) 2004-11-29 2005-11-18 proteìna de fusão compreendendo um domìnio de bh3 de uma proteìna de bh3 somente

Country Status (11)

Country Link
US (1) US20080274956A1 (pt)
EP (2) EP1661912A1 (pt)
JP (1) JP2008521759A (pt)
CN (1) CN101068832A (pt)
AR (1) AR051512A1 (pt)
AU (1) AU2005308990A1 (pt)
BR (1) BRPI0516659A (pt)
CA (1) CA2590512A1 (pt)
EA (1) EA013469B1 (pt)
IL (1) IL182460A0 (pt)
WO (1) WO2006056370A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2007035494A2 (en) * 2005-09-16 2007-03-29 The Regents Of The University Of California Inducing expression of puma to reduce joint inflammation in the treatment of arthritis
US7582606B2 (en) * 2005-11-03 2009-09-01 The Board Of Regents Of The University Of Texas System Nadph oxidase cytosolic cofactor mutant
AU2007340162B2 (en) * 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
CN101583274A (zh) * 2006-12-29 2009-11-18 雷文斯治疗公司 使用反向序列hiv-tat多肽的运输分子
US8785388B2 (en) * 2007-02-14 2014-07-22 Saint Louis University TAT-BH3 methods for treating arthritis
CA2694046C (en) 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
CN101580548B (zh) * 2008-05-12 2013-06-05 中国医学科学院肿瘤研究所 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
SG182016A1 (en) * 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140378528A1 (en) 2013-06-24 2014-12-25 Mirna Biomarkers of mir-34 activity
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR101818809B1 (ko) * 2014-07-24 2018-02-21 가톨릭대학교 산학협력단 Bad 발현 촉진제를 포함하는 엡스타인-바 바이러스 감염증 치료용 조성물
SI3377634T1 (sl) * 2015-11-19 2021-01-29 Universitaet Basel Dostava na bakterijah osnovanih proteinov
WO2023031215A2 (en) * 2021-09-02 2023-03-09 Umc Utrecht Holding B.V. Pro-apoptotic construct and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082310A4 (en) * 1998-04-29 2001-09-12 Univ Georgetown METHODS RELATING TO THE IDENTIFICATION AND USE OF COMPOUNDS THAT BIND TO HLA MOLECULES AS AGONISTS OR ANTAGONISTS TO HLA
EP1076711A2 (en) * 1998-05-13 2001-02-21 Incyte Pharmaceuticals, Inc. Human apoptosis associated proteins
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
EP1181306A4 (en) * 1999-05-28 2003-06-18 Apoptosis Technology Inc COMPOUNDS AND METHODS FOR REGULATING APOPTOSIS, AND METHODS OF MAKING AND SCREENING REGULATORY COMPOUNDS FOR APOPTOSIS
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2003008553A2 (en) * 2001-07-17 2003-01-30 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
AU2003267124A1 (en) * 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
KR100685345B1 (ko) * 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드

Also Published As

Publication number Publication date
JP2008521759A (ja) 2008-06-26
AU2005308990A1 (en) 2006-06-01
US20080274956A1 (en) 2008-11-06
EP1817334A1 (en) 2007-08-15
AR051512A1 (es) 2007-01-17
CA2590512A1 (en) 2006-06-01
WO2006056370A1 (en) 2006-06-01
EP1661912A1 (en) 2006-05-31
CN101068832A (zh) 2007-11-07
EA200700973A1 (ru) 2007-12-28
EA013469B1 (ru) 2010-04-30
IL182460A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
BRPI0516659A (pt) proteìna de fusão compreendendo um domìnio de bh3 de uma proteìna de bh3 somente
IL187168A (en) Proteins or polypeptides containing two identical nanobedis against Factor von Willebrand, methods for their preparation, medicinal preparations containing them and their use
BRPI0820956A8 (pt) Composição nutricional enteral líquida esterilizada, método para produzir a composição, uso de uma composição nutricional, e, uso simultâneo ou seqüencial de caseína micelar e, opcionalmente, caseinato
DK1791571T3 (da) Radiofluorinerede peptider
DOP2007000089A (es) Proteínas de fusión rag, formulaciones y métodos de empleos de las mismas
CO6180433A2 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
UY31123A1 (es) Proteinas de fusion natriureticas
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
UY31533A1 (es) Moleculas de enlace al receptor humano ox40
DK1948235T3 (da) Fremgangsmåder til bestemmelse af effektiviteten af adalimumab hos patienter med Bechterews sygdom med CTX-II og MMP3 som biomarkører
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
CL2009000459A1 (es) Anticuerpo se une a la proteina rgm a; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; construccion de anticuerpos que comprende dicha proteina; conjugado de anticuerpos que comprende a la construccion; uso.
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
ECSP088262A (es) Proteínas de fusión de albúmina
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
ME00185B (me) Specifični agensi koji vezuju humani angiopoetin-2
CL2010000720A1 (es) Método para la evaluar la respuesta a la inhibición de her en una muestra de paciente, que comprende detectar la proteina marcadora egf (div.sol.no. 1240-06).
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
ATE480568T1 (de) Verbesserte sgp 130fc dimere
ATE451916T1 (de) Ophthalmische pharmazeutische zusammensetzungen auf basis von aminosäuren und natriumhyaluronat
DK1364029T3 (da) Fusionsprotein, der omfatter hirudin og proinsulin eller insulin
ATE498683T1 (de) Leptin antagonisten
BRPI0416544A (pt) proteìna de ligação de gag
AR082502A1 (es) Proteinas osteogenicas de diseño

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.